COMPASS Pathways has received Breakthrough Therapy designation from the US Food and Drug Administration for its psilocybin therapy for treatment-resistant depression. Breakthrough Therapy designation is a significant milestone for psilocybin therapy and psilocybin research, and a testament to the work done over many years by research teams in the US, the UK and Switzerland. The Heffter Research Institute was the first to fund research in this field, and supported early studies at Johns Hopkin...